Cite
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
MLA
Rayson, Daniel, et al. “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.” Current Oncology, vol. 29, no. 12, Dec. 2022, pp. 9891–95. EBSCOhost, https://doi.org/10.3390/curroncol29120778.
APA
Rayson, D., Gandhi, S., Joy, A. A., Brezden-Masley, C., Gelmon, K. A., Sehdev, S., Cescon, D., & Chia, S. (2022). Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Current Oncology, 29(12), 9891–9895. https://doi.org/10.3390/curroncol29120778
Chicago
Rayson, Daniel, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, and Stephen Chia. 2022. “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.” Current Oncology 29 (12): 9891–95. doi:10.3390/curroncol29120778.